Haematology and Lymphoid Malignancies
Clinical research includes classical Hodgkin lymphoma, relapsed/refractory chronic lymphocytic leukaemia, small lymphocytic lymphoma, Richter transformation, multiple myeloma, and primary central nervous system lymphoma. The portfolio also covers high-risk chronic lymphocytic leukaemia and treatment approaches for older or frail patients.
- Classical Hodgkin lymphoma
- Chronic lymphocytic leukaemia
- Richter transformation
- Multiple myeloma
- Primary CNS lymphoma
Research activity spans immunotherapy, BTK inhibition, BCL2-targeted therapy, and anti-CD20-based combinations across aggressive and indolent haematological disease.
Ophthalmology and Corneal Disease
Trials address corneal neovascularization in aniridia-associated keratopathy and herpetic keratopathy, with interest in preserving corneal structure before high-risk keratoplasty. The work also includes pathological vascularisation affecting transplant candidacy.
- Corneal neovascularization
- Aniridia-associated keratopathy
- Herpetic keratopathy
- High-risk keratoplasty
Research in this area focuses on anti-neovascular eye treatments and corneal surface preservation strategies.
Rare Genetic and Neurological Disorders
Investigator-initiated studies include GNAO1-associated disorders, autosomal dominant polycystic kidney disease, and neuroblastoma. These programmes reflect interest in inherited disease mechanisms and paediatric oncology.
- GNAO1-associated disorders
- Autosomal dominant polycystic kidney disease
- Low- and intermediate-risk neuroblastoma
Therapeutic areas include orphan neurological disease, renal disease, and risk-adapted paediatric treatment.
Solid Tumours and Thoracic Oncology
Research extends to small-cell lung cancer and pancreatic adenocarcinoma with oligometastatic liver involvement. The oncology portfolio also includes treatment strategies for advanced or metastatic solid tumours.
- Small-cell lung cancer
- Pancreatic adenocarcinoma
- Hepatic oligometastatic disease
Key therapeutic interests include checkpoint inhibition, maintenance therapy, and curative-intent multimodal treatment in solid tumour care.
